Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Is a non-smoker or is a moderate smoker for at least 3 months prior to dosing
Participants with Mild and Moderate HI
Is classified as having either mild HI (Group 1) or moderate HI (Group 2) score on the Child-Pugh scale ranging from 5 to 6 (mild) or 7 to 9 (moderate)
Has a diagnosis of chronic (\> 6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology
Healthy Control Participants:
Must match the mean age (± 15 years) of participants with mild HI and moderate HI
Must match the mean body-mass index (BMI) (± 25%) of participants with mild HI (Group 1) and moderate HI
Must match the sex ratio (±2) of participants in each HI group, separately
You may not be if
All Participants
History of cancer (malignancy)
Female participants of childbearing potential
Is positive for Hepatitis C virus (HCV)
Is positive for Hepatitis B surface antigen (HBsAg)
Is positive for human immunodeficiency virus (HIV)
Participants with Mild and Moderate HI
Has any significant arrhythmia or conduction abnormality
Severe complications of liver disease within the preceding 3 months
Primary biliary cholangitis or biliary obstruction
Has a history of a recent variceal bleeds
Has evidence of hepatorenal syndrome
Has a history of liver or other solid organ transplantation
Has an active infection requiring systemic therapy
Requires paracentesis more often than 2 times per month
Has transjugular intrahepatic portosystemic shunt and/or has undergone portacaval shunting
Healthy Control Participants
Has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
Is a regular user of cannabis products within approximately 6 months of study
Clareo Health | A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)
